Monopar Therapeutics Inc. (MNPR) vs Prime Medicine, Inc. (PRME)
Monopar Therapeutics Inc. and Prime Medicine, Inc. are both Biotechnology companies. Monopar Therapeutics Inc. and Prime Medicine, Inc. are of similar size ($609.4M and $602.8M). Monopar Therapeutics Inc. has the higher net margin (0.00% vs −4,613.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 11 metrics below, Monopar Therapeutics Inc. leads on 10 and Prime Medicine, Inc. on 1.
Valuation
Profitability
| Metric | MNPR | PRME | Biotechnology median |
|---|---|---|---|
| Gross margin | — | 100.00% | 65.16% |
| Operating margin | 0.00% | (4,824.94%) | 0.00% |
| Net margin | 0.00% | (4,613.11%) | 0.00% |
| Free cash flow margin | 0.00% | (3,850.92%) | 0.00% |
| Return on equity | (19.50%) | (373.29%) | (57.72%) |
| Return on assets | (18.90%) | (71.16%) | (49.22%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack